Ch.1: Defining the Problem
Ch.2: Prostate Cancer Screening: Navigating the Controversy
Ch.3: Is the PSA Era Over?
Ch.4: PSA Dynamics
Ch.5: Percent Free PSA
Ch.6: PCA3 and other Urinary Markers
Ch.7: Blood-Based Tumor Markers for Prostate Cancer
Ch.8: Prediction Models in Prostate Cancer Diagnosis and Preparation for Biopsy
Ch.9: Is There a Role for Medications to Reduce the Need for Prostate Biopsy?
Ch.10: Indications For Initial Biopsy: Is The PSA Threshold Over?
Ch.11: Preparation for Prostate Biopsy
Ch.12: Pain Prevention
Ch.13: Prostate Biopsy
Ch.14: Prostate Biopsy Techniques
Ch.15: Transperineal Biopsy
Ch.16: Pathological Implications of Prostate Biopsy
Ch.17: Complications of Transrectal Ultrasound Guided Prostate Biopsy
Ch.18: After the Biopsy: Management of High Grade Prostatic Intraepithelial Neoplasia (HGPIN)
Ch.19: Atypical Small Acinar Proliferation
Ch.20: Repeat Prostate Biopsy Strategies - Indications and Techniques
Ch.21: Transperineal Mapping Biopsy of the Prostate for Assessment of the Minimal Risk Patient
Ch.22: Management of the Patient Following a Negative Biopsy: Saturation Biopsy
Ch.23: Role of imaging as an adjunct or replacement for biopsy: American Experience
Ch.24: Role Of Imaging As An Adjunct Or Replacement For Biopsy: European Experience
Ch.25: Prostate Cancer Detection: Lessons Learnt in the Cleveland Clinic Experience with Focus on the Negative Biopsy
Ch.26: Future Directions in Prostate Cancer Diagnosis
